Antibodies and Immunotoxins that Target Human Glycoprotein NMB
Description of Invention:
The human transmembrane glycoprotein NMB (GPNMB) and a splice variant form are highly expressed in the cells of several forms of brain cancer when compared to normal brain cells. This invention combines Pseudomonas exotoxin (PE) attached to an Fv antibody fragment that targets cells expressing GPNMB but not GPNMB-negative or normal cells. Results show that this antibody-immunotoxin conjugate inhibits the growth of cells expressing human glycoprotein GPNMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells and melanoma cells.
Inventors:
Ira Pastan (NCI) et al.
Patent Status:
DHHS Reference No. E-003-2006/0 --
U.S. Provisional Application No. 60/732,227 filed 31 Oct 2005
PCT Application No. PCT/US2006/042735 filed 31 Oct 2006
Portfolios: Cancer
Cancer -Therapeutics-Immunoconjugates Cancer -Therapeutics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
